Somatostatin analogues in the treatment of breast and prostate cancer.
Newly developed somatostatin analogues may be useful agents in the treatment of breast and prostate cancer. Potential mechanisms of antitumor action include suppression of circulating levels of trophic hormones and growth factors as well as direct effects at the tumor level, potentially involving autocrine/paracrine mechanisms. Pilot clinical trials conducted in heavily pretreated women with advanced breast cancer indicate that SMS 201-995 (Sandostatin R) has minimal toxicity and moderately suppresses stimulated growth hormone secretion and basal somatomedin-C level. Somatostatin analogues have also been found to retard the growth of experimental prostate cancer, particularly when used in combination with LHRH analogues. The therapeutic efficacy of these compounds used alone or in combination with other agents in the treatment of breast and prostate cancer remains to be established in larger clinical trials involving less heavily pretreated patients.
Manni
A
A
Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Boucher
A E
AE
Demers
L M
LM
Harvey
H A
HA
Lipton
A
A
Simmonds
M A
MA
Bartholomew
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D006133:Growth Substances; D013004:Somatostatin